|
1
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Isharwal S and Konety B: Non-muscle
invasive bladder cancer risk stratification. Indian J Urol.
31:289–296. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kamat AM, Hahn NM, Efstathiou JA, Lerner
SP, Malmström PU, Choi W, Guo CC, Lotan Y and Kassouf W: Bladder
cancer. Lancet. 388:2796–2810. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Herr HW: Tumor progression and survival of
patients with high grade, noninvasive papillary (TaG3) bladder
tumors: 15-year outcome. J Urol. 163:60–62. 2000.PubMed/NCBI
|
|
5
|
Park JC, Citrin DE, Agarwal PK and Apolo
AB: Multimodal management of Muscle-invasive bladder cancer. Curr
Probl Cancer. 38:80–108. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mossanen M and Gore JL: The burden of
bladder cancer care: Direct and indirect costs. Curr Opin Urol.
24:487–491. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kim LHC and Patel MI: Transurethral
resection of bladder tumour (TURBT). Transl Androl Urol.
9:3056–3072. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Herr HW and Donat SM: Quality control in
transurethral resection of bladder tumours. BJU Int. 102:1242–1246.
2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Martin-Doyle W, Leow JJ, Orsola A, Chang
SL and Bellmunt J: Improving selection criteria for early
cystectomy in high-grade T1 bladder cancer: A meta-analysis of
15,215 patients. J Clin Oncol. 33:643–50. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Babjuk M, Oosterlinck W, Sylvester R,
Kaasinen E, Böhle A and Palou J: others: EAU guidelines on
non-muscle invasive bladder cancer (TaT1 and CIS). Eur Urol,
2021.
|
|
11
|
Sylvester RJ, Oosterlinck W and Van Der
Meijden APM: A single immediate postoperative instillation of
chemotherapy decreases the risk of recurrence in patients with
stage Ta T1 bladder cancer: A meta-analysis of published results of
randomized clinical trials. J Urol. 171:2186–2190. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Maa Y, Djatisoesanto W and Hardjowijoto S:
Profile of bladder transitional cell cancer in Soetomo Hospital
Surabaya. Indones J Urol. 21:1–6. 2014.
|
|
13
|
Porten SP, Leapman MS and Greene KL:
Intravesical chemotherapy in Non-muscle-invasive bladder cancer.
Indian J Urol. 31:297–303. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
in nBean J and Sylvester R: Results of
EORTC Genito-Urinary Group phase III trial 30911 [Internet]. 2010
Mar 12 [cited 2025 Aug 22]. Available from: EORTC website.
|
|
15
|
Sylvester RJ, van der MEIJDEN AP and Lamm
DL: Intravesical bacillus Calmette-Guerin reduces the risk of
progression in patients with superficial bladder cancer: A
meta-analysis of the published results of randomized clinical
trials. J Urol. 168:1964–1970. 2002.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gontero P, Oderda M, Mehnert A, Gurioli A,
Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, et al:
The impact of intravesical gemcitabine and 1/3 dose bacillus
Calmette-Guérin instillation therapy on the quality of life in
patients with nonmuscle invasive bladder cancer: Results of a
prospective, randomized, phase II trial. J Urol. 190:857–862.
2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Porena M, Del Zingaro M, Lazzeri M,
Mearini L, Giannantoni A, Bini V and Costantini E: Bacillus
calmette-guérin versus gemcitabine for intravesical therapy in
high-risk superficial bladder cancer: A randomised prospective
study. Urol Int. 84:23–27. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Di Lorenzo G, Perdonà S, Damiano R,
Faiella A, Cantiello F, Pignata S, Ascierto P, Simeone E, De Sio M
and Autorino R: Gemcitabine versus bacille Calmette-Guérin after
initial bacille Calmette-Guérin failure in non-muscle-invasive
bladder cancer: A multicenter prospective randomized trial. Cancer.
116:1893–1900. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bendary L, Khalil S, Shahin A and Nawar N:
1655 intravesical gemcitabine versus bacillus Calmette-Guerin (BCG)
in treatment of non-muscle invasive bladder cancer: Short term
comparative study. J Urol. 185:e664–e665. 2011.
|
|
20
|
Prasanna T, Craft P, Balasingam G,
Haxhimolla H and Pranavan G: Intravesical gemcitabine versus
intravesical bacillus calmette-guérin for the treatment of
Non-muscle invasive bladder cancer: An evaluation of efficacy and
toxicity. Front Oncol. 7:1–5. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Boehm BE, Cornell JE, Wang H, Mukherjee N,
Oppenheimer JS and Svatek RS: Efficacy of bacillus Calmette-guérin
strains for treatment of nonmuscle invasive bladder cancer: A
systematic review and network Meta-Analysis. J Urol. 198:503–510.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shelley MD, Jones G, Cleves A, Wilt TJ,
Mason MD and Kynaston HG: Intravesical gemcitabine therapy for
non-muscle invasive bladder cancer (NMIBC): A systematic review.
BJU Int. 109:496–505. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jones G, Cleves A, Wilt TJ, Mason M,
Kynaston HG and Shelley M: Intravesical gemcitabine for non-muscle
invasive bladder cancer. Cochrane database Syst Rev.
1(CD009294)2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lu JL, Xia QD, Lu YH, Liu Z, Zhou P, Hu HL
and Wang SG: Efficacy of intravesical therapies on the prevention
of recurrence and progression of non-muscle-invasive bladder
cancer: A systematic review and network meta-analysis. Cancer Med.
9:7800–7809. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hurle R, Casale P, Morenghi E, Saita A,
Buffi N, Lughezzani G, Colombo P, Contieri R, Frego N, Guazzoni G
and Lazzeri M: Intravesical gemcitabine as bladder-preserving
treatment for BCG unresponsive non-muscle-invasive bladder cancer.
Results from a single-arm, open-label study. BJUI Compass.
1:126–132. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Maroof H, Paramore L and Ali A: Theories
behind bacillus Calmette-Guérin failure in high-risk
non-muscle-invasive bladder cancer and update on current
management. Cancer Pathog Ther. 2:74–80. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jiang S and Redelman-Sidi G: BCG in
bladder cancer immunotherapy. Cancers (Basel).
14(3073)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Akbulut I, Ödemiş İ and Atalay S: Analysis
of local and systemic side effects of bacillus Calmette-Guérin
immunotherapy in bladder cancer: A retrospective study in Türkiye.
PeerJ. 13(e18870)2025.PubMed/NCBI View Article : Google Scholar
|
